MX362061B - Ácidos nucleicos de enlace c5a nuevos. - Google Patents
Ácidos nucleicos de enlace c5a nuevos.Info
- Publication number
- MX362061B MX362061B MX2014008454A MX2014008454A MX362061B MX 362061 B MX362061 B MX 362061B MX 2014008454 A MX2014008454 A MX 2014008454A MX 2014008454 A MX2014008454 A MX 2014008454A MX 362061 B MX362061 B MX 362061B
- Authority
- MX
- Mexico
- Prior art keywords
- new
- nucleic acids
- binding nucleic
- nucleic acid
- acid molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención se refiere a una molécula de ácido nucleico con la capacidad de enlazar a C5a humano, en donde la molécula de ácido nucleico comprende una extensión central de nucleótidos, en donde la extensión central de nucleótidos comprende una secuencia de nucleótido de 5' AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3' [SEQ ID NO: 61], en donde n1 es U o dU, n2 es G o dG, n3 es A o dA, n4 es U o dU,n5 es U o dU y G, A , U , C ,H, K y R son ribonucleótidos, y dU, dG y dA son 2'-desoxirribonucleótidos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
EP12000106 | 2012-01-10 | ||
EP12006960 | 2012-10-08 | ||
PCT/EP2013/000056 WO2013104540A1 (en) | 2012-01-10 | 2013-01-10 | New c5a binding nucleic acids |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008454A MX2014008454A (es) | 2015-02-05 |
MX362061B true MX362061B (es) | 2019-01-07 |
Family
ID=48781063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008454A MX362061B (es) | 2012-01-10 | 2013-01-10 | Ácidos nucleicos de enlace c5a nuevos. |
Country Status (19)
Country | Link |
---|---|
US (3) | US9518265B2 (es) |
EP (1) | EP2802660B1 (es) |
JP (1) | JP6415327B2 (es) |
KR (1) | KR102034203B1 (es) |
CN (1) | CN104145018B (es) |
AU (2) | AU2013209131A1 (es) |
BR (1) | BR112014016877B1 (es) |
CA (1) | CA2860806C (es) |
DK (1) | DK2802660T3 (es) |
ES (1) | ES2786007T3 (es) |
HK (1) | HK1198371A1 (es) |
IL (1) | IL233516B (es) |
IN (1) | IN2014DN05665A (es) |
MX (1) | MX362061B (es) |
PL (1) | PL2802660T3 (es) |
PT (1) | PT2802660T (es) |
RU (1) | RU2645261C2 (es) |
SG (2) | SG11201403771SA (es) |
WO (1) | WO2013104540A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015066027A2 (en) | 2013-10-28 | 2015-05-07 | Dots Devices, Inc. | Allergen detection |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
US11172873B2 (en) | 2018-05-17 | 2021-11-16 | The Procter & Gamble Company | Systems and methods for hair analysis |
JP7140848B2 (ja) | 2018-05-17 | 2022-09-21 | ザ プロクター アンド ギャンブル カンパニー | 毛髪被覆率分析のためのシステム及び方法 |
EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
EP3814504A1 (en) | 2018-06-29 | 2021-05-05 | The Procter & Gamble Company | Aptamers for personal care applications |
SG11202104432YA (en) * | 2018-11-12 | 2021-05-28 | Aptarion Biotech Ag | Cxcl8 binding nucleic acids |
US11806419B2 (en) | 2019-04-16 | 2023-11-07 | The Procter & Gamble Company | Aptamers for odor control applications |
CN113150106B (zh) * | 2021-04-26 | 2022-08-16 | 华中农业大学 | 来源于补体成分C5a的抗菌肽及其应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
DK2431377T3 (en) | 2001-10-26 | 2017-08-14 | Noxxon Pharma Ag | Modified L-nucleic acids |
EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
EP1585817B1 (en) | 2002-02-20 | 2009-09-02 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
RU2394041C2 (ru) | 2003-04-13 | 2010-07-10 | Энзон Фармасьютикалз, Инк. | Полимерные олигонуклеотидные пролекарства |
GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
WO2005074993A2 (de) | 2004-02-09 | 2005-08-18 | Noxxon Pharma Ag | Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden |
DK2860251T3 (en) * | 2004-02-12 | 2018-06-06 | Archemix Llc | APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
EP1838725A1 (en) * | 2005-01-17 | 2007-10-03 | Jerini AG | C5a receptor antagonists |
BRPI0708588A2 (pt) | 2006-03-08 | 2011-06-07 | Archemix Corp | aptámeros de ligaçao ao complemento e agentes anti-c5 usados no tratamento de desordens oculares |
CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
EP2407558A1 (en) | 2006-10-31 | 2012-01-18 | Noxxon Pharma AG | Methods for the detection of a single- or double-stranded nucleic acid molecule |
CA2700441A1 (en) * | 2007-09-24 | 2009-04-02 | Noxxon Pharma Ag | C5a binding nucleic acids |
EP2407082B1 (en) | 2009-03-11 | 2017-04-26 | Olympus Corporation | Image processing system, external device and image processing method |
US20120065254A1 (en) | 2009-03-23 | 2012-03-15 | Noxxon Pharma Ag | C5A binding nucleic acids and the use thereof |
WO2011131371A1 (en) | 2010-04-21 | 2011-10-27 | Noxxon Pharma Ag | Lipid binding nucleic acids |
KR20140026357A (ko) * | 2011-01-10 | 2014-03-05 | 녹손 파르마 아게 | 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법 |
JP2014533098A (ja) | 2011-10-21 | 2014-12-11 | ノクソン・ファルマ・アクチエンゲゼルシャフト | グルカゴン結合核酸 |
CN104136612A (zh) | 2012-01-10 | 2014-11-05 | 诺松制药股份公司 | 特异性结合cgrp的核酸 |
-
2013
- 2013-01-10 KR KR1020147022321A patent/KR102034203B1/ko active IP Right Grant
- 2013-01-10 PT PT137006177T patent/PT2802660T/pt unknown
- 2013-01-10 CA CA2860806A patent/CA2860806C/en active Active
- 2013-01-10 EP EP13700617.7A patent/EP2802660B1/en active Active
- 2013-01-10 US US14/371,006 patent/US9518265B2/en active Active
- 2013-01-10 PL PL13700617T patent/PL2802660T3/pl unknown
- 2013-01-10 SG SG11201403771SA patent/SG11201403771SA/en unknown
- 2013-01-10 WO PCT/EP2013/000056 patent/WO2013104540A1/en active Application Filing
- 2013-01-10 AU AU2013209131A patent/AU2013209131A1/en not_active Abandoned
- 2013-01-10 SG SG10201605594UA patent/SG10201605594UA/en unknown
- 2013-01-10 DK DK13700617.7T patent/DK2802660T3/da active
- 2013-01-10 ES ES13700617T patent/ES2786007T3/es active Active
- 2013-01-10 MX MX2014008454A patent/MX362061B/es active IP Right Grant
- 2013-01-10 RU RU2014132708A patent/RU2645261C2/ru active
- 2013-01-10 BR BR112014016877-6A patent/BR112014016877B1/pt active IP Right Grant
- 2013-01-10 CN CN201380009020.9A patent/CN104145018B/zh active Active
- 2013-01-10 IN IN5665DEN2014 patent/IN2014DN05665A/en unknown
- 2013-01-10 JP JP2014551570A patent/JP6415327B2/ja active Active
-
2014
- 2014-07-03 IL IL233516A patent/IL233516B/en active IP Right Grant
- 2014-11-24 HK HK14111874.2A patent/HK1198371A1/xx unknown
-
2016
- 2016-12-12 US US15/376,338 patent/US10590424B2/en active Active
-
2018
- 2018-11-30 AU AU2018271388A patent/AU2018271388B2/en active Active
-
2020
- 2020-03-15 US US16/819,102 patent/US11492625B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014008454A (es) | Acidos nucleicos de enlace c5a nuevos. | |
CY1120685T1 (el) | Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47 | |
WO2014028429A3 (en) | Enzymes and polymerases for the synthesis of rna | |
WO2014096992A8 (en) | Acetyl transferases and their use for producing carotenoids | |
RS54649B1 (en) | NUCLEIC ACID ANTISENS | |
IN2014DN03463A (es) | ||
WO2011079902A3 (en) | Biological inhibitors of ror1 capable of inducing cell death | |
MX2011003229A (es) | Terapia genica con porfobilinogeno desaminasa. | |
MX2013007678A (es) | Moleculas de acido nucleico dirigidas ala pequeña proteina de union de gtp rho1 y que confieren resistencia a las plagas de coleopteros. | |
NZ607870A (en) | Lactococcus crispr-cas sequences | |
EA201490534A1 (ru) | Способы мечения днк-кодированных библиотек | |
WO2013090457A3 (en) | In vivo delivery of oligonucleotides | |
IN2012DN00403A (es) | ||
MX2013007286A (es) | Construccion de adn inmunomoduladora no codificante. | |
MX356625B (es) | Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva. | |
EP2274442A4 (en) | CONSENSUS SEQUENCES OF CHIKUNGUNYA VIRUS PROTEINS, NUCLEIC ACID MOLECULES ENCODING SAME, AND COMPOSITIONS AND METHODS OF USE THEREOF | |
AU2014219019A8 (en) | Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage | |
MX2010003109A (es) | Acidos nucleicos de enlace c5a. | |
EA201101627A1 (ru) | Рекомбинантные бактерии и их применение для получения этанола | |
AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
WO2012046084A3 (en) | Short rna molecules | |
NZ700902A (en) | Lowering saturated fatty acid content of plant seeds | |
MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
WO2010107955A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING | |
EP2488641A4 (en) | SURENROUTED MINICERCLED DNA FOR GENE THERAPY APPLICATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |